Skip Navigation



QJM Advance Access published online on June 9, 2006
QJM, doi:10.1093/qjmed/hcl059
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/7/431    most recent
hcl059v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sarafidis, P.A.
Right arrow Articles by Bakris, G.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarafidis, P.A.
Right arrow Articles by Bakris, G.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: Journals.permissions@oxfordjournals.org

Review

Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control

P.A. Sarafidis 1 * and G.L. Bakris 1

1 From the Hypertension/Clinical Research Center, Departments of Preventive and Internal Medicine, Rush University Medical Center, Chicago, USA

* To whom correspondence should be addressed.
P.A. Sarafidis, E-mail: psarafidis11{at}yahoo.gr


  Abstract

Hypertension and type 2 diabetes mellitus (DM) are major cardiovascular risk factors, and often cluster in the same individual in the context of the metabolic syndrome. Management of hypertension in the diabetic patient is extremely important, and agents from all major antihypertensive classes are effective towards this goal. Conventional {beta}-blockers are associated with detrimental effects on insulin sensitivity, glycaemic control, and the incidence of type 2 DM and thus are less often used in hypertensive patients with DM. In contrast, the newer vasodilating {beta}-blockers appear to be free of adverse effects on the above metabolic parameters, and could be a valuable tool for hypertension treatment in patients with DM or the metabolic syndrome. This review summarizes the evidence on the effects of antihypertensive treatment with both traditional and vasodilating {beta}-blockers on parameters related to carbohydrate metabolism, and discuss the pathophysiological mechanisms that may be responsible.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
R. Izzo, G. de Simone, M. Chinali, G. Iaccarino, V. Trimarco, F. Rozza, R. Giudice, B. Trimarco, and N. De Luca
Insufficient Control of Blood Pressure and Incident Diabetes
Diabetes Care, May 1, 2009; 32(5): 845 - 850.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.